Enlivex Therapeutics Stock Current Valuation
| ENLV Stock | USD 0.84 0.14 14.29% |
Valuation analysis of Enlivex Therapeutics helps investors to measure Enlivex Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -1.87 in 2024. Enterprise Value Multiple is likely to drop to -1.87 in 2024. Fundamental drivers impacting Enlivex Therapeutics' valuation include:
Price Book 0.7315 | Enterprise Value -4.2 M | Enterprise Value Ebitda (1.49) |
Overvalued
Today
Please note that Enlivex Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Enlivex Therapeutics is based on 3 months time horizon. Increasing Enlivex Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Enlivex stock is determined by what a typical buyer is willing to pay for full or partial control of Enlivex Therapeutics. Since Enlivex Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enlivex Stock. However, Enlivex Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.84 | Real 0.81 | Target 12.0 | Hype 0.84 | Naive 0.77 |
The intrinsic value of Enlivex Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Enlivex Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Enlivex Therapeutics helps investors to forecast how Enlivex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enlivex Therapeutics more accurately as focusing exclusively on Enlivex Therapeutics' fundamentals will not take into account other important factors: Enlivex Therapeutics Company Current Valuation Analysis
Enlivex Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Enlivex Therapeutics Current Valuation | (4.21 M) |
Most of Enlivex Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enlivex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enlivex Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Enlivex Therapeutics is extremely important. It helps to project a fair market value of Enlivex Stock properly, considering its historical fundamentals such as Current Valuation. Since Enlivex Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enlivex Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enlivex Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enlivex Current Valuation Historical Pattern
Today, most investors in Enlivex Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Enlivex Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Enlivex Therapeutics current valuation as a starting point in their analysis.
Enlivex Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Enlivex Therapeutics has a Current Valuation of (4.21 Million). This is 100.03% lower than that of the Software sector and 100.09% lower than that of the Information Technology industry. The current valuation for all United States stocks is 100.03% higher than that of the company.
Enlivex Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enlivex Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enlivex Therapeutics could also be used in its relative valuation, which is a method of valuing Enlivex Therapeutics by comparing valuation metrics of similar companies.Enlivex Therapeutics is currently under evaluation in current valuation category among its peers.
Enlivex Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Enlivex Therapeutics from analyzing Enlivex Therapeutics' financial statements. These drivers represent accounts that assess Enlivex Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Enlivex Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 72.6M | 111.0M | 111.6M | 72.5M | 50.2M | 50.2M | |
| Enterprise Value | 68.7M | 105.5M | 101.0M | 29.5M | 50.3M | 41.9M |
Enlivex Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | (4.21 M) | ||||
| Shares Outstanding | 21.41 M | ||||
| Shares Owned By Insiders | 5.73 % | ||||
| Shares Owned By Institutions | 18.80 % | ||||
| Number Of Shares Shorted | 160.14 K | ||||
| Price To Earning | (11.97) X | ||||
| Price To Book | 0.73 X | ||||
| EBITDA | (28.22 M) | ||||
| Net Income | (29.07 M) | ||||
| Cash And Equivalents | 62.48 M | ||||
| Cash Per Share | 3.40 X | ||||
| Total Debt | 1.03 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 15.44 X | ||||
| Book Value Per Share | 1.37 X | ||||
| Cash Flow From Operations | (23.52 M) | ||||
| Short Ratio | 1.23 X | ||||
| Earnings Per Share | (1.18) X | ||||
| Target Price | 9.5 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 18 M | ||||
| Total Asset | 36.83 M | ||||
| Retained Earnings | (112.09 M) | ||||
| Working Capital | 27.7 M | ||||
| Current Asset | 6 M | ||||
| Current Liabilities | 671.32 K | ||||
| Net Asset | 36.83 M |
About Enlivex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enlivex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enlivex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enlivex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.